The Use of GPCR Structures in Drug Design

Advances in Pharmacology

Volumn 62, Issue , 2011, Pages 1-36

  Congreve, Miles ^a   Langmead, Christopher ^a   Marshall, Fiona H ^a  

^a Heptares Therapeutics Ltd   (United Kingdom)

Author keywords

Drug discovery; G protein coupled receptor; Structure based drug discovery

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE A2A RECEPTOR; ANTINEOPLASTIC AGENT; ASTEMIZOLE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BI 167107; CARAZOLOL; CARMETEROL; CHEMOKINE RECEPTOR CXCR4; CYANOPINDOLOL; DASATINIB; DOBUTAMINE; ERLOTINIB; ETICLOPRIDE; FAUC 50; G PROTEIN COUPLED RECEPTOR; IMATINIB; ISOPRENALINE; LAPATINIB; NILOTINIB; OSELTAMIVIR; PARTIAL AGONIST; PHOSPHOTRANSFERASE INHIBITOR; RHODOPSIN; SALBUTAMOL; SB 265610; SOMATOSTATIN RECEPTOR 5; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZANAMIVIR; [4 [(3 CHLOROPHENYL)CARBAMOYLOXY] 2 BUTYNYL]TRIMETHYLAMMONIUM;

BOOK; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; THERMOSTABILITY;

EID: 80052690961     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385952-5.00011-7     Document Type: Chapter

References (122)

1. Albert J.S., Blomberg N., Breeze A.L., Brown A.J., Burrows J.N., Edwards P.D., et al. An integrated approach to fragment-based lead generation: Philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. Current Topics in Medicinal Chemistry 2007, 7(16):1600-1629.
2. Allegretti M., Bertini R., Cesta M.C., Bizzarri C., Di Bitondo R., Di Cioccio V., et al. 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. Journal of Medicinal Chemistry 2005, 48(13):4312-4331.
3. Andrews G., Jones C., Wreggett K.A. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Molecular Pharmacology 2008, 73(3):855-867.
4. Ballesteros J.A., Weinstein H., Stuart C.S. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods in Neurosciences 1995, 25:366-428.
5. Barton N., Blaney F.E., Garland S., Tehan B., Wall I. Seven transmembrane G protein-coupled receptors: Insights for drug design from structure and modeling. Comprehensive Medicinal Chemistry II 2007, 4:669-701.
6. Blaney F.E., Capelli A.M., Tedesco G. 7TM models in structure-based drug design ligand design for G protein-coupled receptors. Methods and Principles in Medicinal Chemistry 2006, Vol. 30:205-239. Wiley-VCH Verlag GmbH and Co. KgaA, Weinham. R. Didier (Ed.).
7. Bondensgaard K., Ankersen M., Thogersen H., Hansen B.S., Wulff B.S., Bywater R.P. Recognition of privileged structures by G-protein coupled receptors. Journal of Medicinal Chemistry 2004, 47(4):888-899.
8. Burstein E.S., Spalding T.A., Brann M.R. The second intracellular loop of the m5 muscarinic receptor is the switch which enables G-protein coupling. The Journal of Biological Chemistry 1998, 273(38):24322-24327.
9. Caffrey M. Crystallizing membrane proteins for structure determination: Use of lipidic mesophases. Annual Review of Biophysics 2009, 38:29-51.
10. Carlsson J., Yoo L., Gao Z.G., Irwin J.J., Shoichet B.K., Jacobson K.A. Structure-based discovery of A2A adenosine receptor ligands. Journal of Medicinal Chemistry 2010, 53(9):3748-3755.
11. Cascieri M.A., Koch G.E., Ber E., Sadowski S.J., Louizides D., de Laszlo S.E., et al. Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. The Journal of Biological Chemistry 1999, 274(13):8694-8697.
12. Cashen A.F. Plerixafor hydrochloride: A novel agent for the mobilization of peripheral blood stem cells. Drugs of Today (Barcelona, Spain) 2009, 45(7):497-505.
13. Cavasotto C.N., Phatak S.S. Homology modeling in drug discovery: Current trends and applications. Drug Discovery Today 2009, 14(13-14):676-683.
14. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., et al. High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 2007, 318(5854):1258-1265.
15. Chessari G., Woodhead A.J. From fragment to clinical candidate-A historical perspective. Drug Discovery Today 2009, 14(13-14):668-675.
16. Chien E.Y., Liu W., Zhao Q., Katritch V., Han G.W., Hanson M.A., et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010, 330(6007):1091-1095.
17. Clark-Lewis I., Kim K.S., Rajarathnam K., Gong J.H., Dewald B., Moser B., et al. Structure-activity relationships of chemokines. Journal of Leukocyte Biology 1995, 57(5):703-711.
18. Congreve M., Carr R., Murray C., Jhoti H. A 'rule of three' for fragment-based lead discovery?. Drug Discovery Today 2003, 8(19):876-877.
19. Congreve M., Chessari G., Tisi D., Woodhead A.J. Recent developments in fragment-based drug discovery. Journal of Medicinal Chemistry 2008, 51(13):3661-3680.
20. Congreve M., Murray C.W., Blundell T.L. Structural biology and drug discovery. Drug Discovery Today 2005, 10(13):895-907.
21. Congreve M., Rich R.L., Myszka D.G., Figaroa F., Siegal G., Marshall F.H. Fragment Screening of Stabilized G-Protein Coupled Receptors Using Biophysical Methods. Methods in Enzymology 2011, 493:115-136.
22. Costanzi S. On the applicability of GPCR homology models to computer-aided drug discovery: A comparison between in silico and crystal structures of the beta2-adrenergic receptor. Journal of Medicinal Chemistry 2008, 51(10):2907-2914.
23. Costanzi S., Siegel J., Tikhonova I.G., Jacobson K.A. Rhodopsin and the others: A historical perspective on structural studies of G protein-coupled receptors. Current Pharmaceutical Design 2009, 15(35):3994-4002.
24. Dahmane T., Damian M., Mary S., Popot J.L., Baneres J.L. Amphipol-assisted in vitro folding of G protein-coupled receptors. Biochemistry 2009, 48(27):6516-6521.
25. Dal Ben D., Lambertucci C., Marucci G., Volpini R., Cristalli G. Adenosine receptor modeling: What does the A2A crystal structure tell us?. Current Topics in Medicinal Chemistry 2010, 10:993-1018.
26. Day P.W., Rasmussen S.G., Parnot C., Fung J.J., Masood A., Kobilka T.S., et al. A monoclonal antibody for G protein-coupled receptor crystallography. Nature Methods 2007, 4(11):927-929.
27. de Graaf C., Rognan D. Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. Journal of Medicinal Chemistry 2008, 51(16):4978-4985.
28. Deupi X., Dolker N., Lopez-Rodriguez M.L., Campillo M., Ballesteros J.A., Pardo L. Structural models of class a G protein-coupled receptors as a tool for drug design: Insights on transmembrane bundle plasticity. Current Topics in Medicinal Chemistry 2007, 7(10):991-998.
29. Druker B.J. Imatinib as a paradigm of targeted therapies. Advances in Cancer Research 2004, 91:1-30.
30. Doré A.S., Robertson N., Errey J.C., Ng I., Hollenstein K., Tehan B., et al. Structure of the adenosine A2A receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure 2011, (In press).
31. Engel S., Skoumbourdis A.P., Childress J., Neumann S., Deschamps J.R., Thomas C.J., et al. A virtual screen for diverse ligands: Discovery of selective G protein-coupled receptor antagonists. Journal of the American Chemical Society 2008, 130(15):5115-5123.
32. Erlanson D.A., McDowell R.S., O'Brien T. Fragment-based drug discovery. Journal of Medicinal Chemistry 2004, 47(14):3463-3482.
33. Errey J., Marshall F. New techniques to express and crystallize GPCRs. GPCR Molecular Pharmacology and Drug Targeting: Shifting Paradigms and New Directions 2010, John Wiley and Sons, New York. A. Gilchrist (Ed.).
34. Este J.A., Cabrera C., De Clercq E., Struyf S., Van Damme J., Bridger G., et al. Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor. Molecular Pharmacology 1999, 55(1):67-73.
35. Faure P., Dubus E., Ijjaali I., Morliere C., Barberan O., Petitet F. Knowledge-based analysis of multi-potent G-protein coupled receptors ligands. European Journal of Medicinal Chemistry 2010, 45(12):5708-5717.
36. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272(5263):872-877.
37. Feng W., Cai J., Pierce W.M., Song Z.H. Expression of CB2 cannabinoid receptor in Pichia pastoris. Protein Expression and Purification 2002, 26(3):496-505.
38. Foord S.M., Marshall F.H. RAMPs: Accessory proteins for seven transmembrane domain receptors. Trends in Pharmacological Sciences 1999, 20(5):184-187.
39. Garland S., Blaney F.E., GPCR Homology model development and application. Burger's Medicinal Chemistry, Drug Discovery and Development, 2010, 279-300.
40. Goddard W.A., Kim S.K., Li Y., Trzaskowski B., Griffith A.R., Abrol R. Predicted 3D structures for adenosine receptors bound to ligands: Comparison to the crystal structure. Journal of Structural Biology 2010, 170(1):10-20.
41. Grace C.R., Perrin M.H., DiGruccio M.R., Miller C.L., Rivier J.E., Vale W.W., et al. NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(35):12836-12841.
42. Grisshammer R., Duckworth R., Henderson R. Expression of a rat neurotensin receptor in Escherichia coli. The Biochemical Journal 1993, 295(Pt 2):571-576.
43. Hansen K.B., Knop F.K., Holst J.J., Vilsboll T. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. International Journal of Clinical Practice 2009, 63(8):1154-1160.
44. Hanson M.A., Cherezov V., Griffith M.T., Roth C.B., Jaakola V.P., Chien E.Y., et al. A specific cholesterol binding site is established by the 2.8 A structure of the human β2-adrenergic receptor. Structure 2008, 16(6):897-905.
45. Hattori K., Orita M., Toda S., Imanishi M., Itou S., Nakajima Y., et al. Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: Part 6. Bioorganic & Medicinal Chemistry Letters 2009, 19(16):4679-4683.
46. Ho T.W., Edvinsson L., Goadsby P.J. CGRP and its receptors provide new insights into migraine pathophysiology. Nature Reviews. Neurology 2010, 6(10):573-582.
47. Hoare S.R. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discovery Today 2005, 10(6):417-427.
48. Hopkins A.L., Groom C.R., Alex A. Ligand efficiency: A useful metric for lead selection. Drug Discovery Today 2004, 9(10):430-431.
49. Huang L.Y., Umanah G., Hauser M., Son C., Arshava B., Naider F., et al. Unnatural amino acid replacement in a yeast G protein-coupled receptor in its native environment. Biochemistry 2008, 47(20):5638-5648.
50. Hunte C. Specific protein-lipid interactions in membrane proteins. Biochemical Society Transactions 2005, 33(Pt 5):938-942.
51. Ivanov A.A., Barak D., Jacobson K.A. Evaluation of homology modeling of G-protein-coupled receptors in light of the A2A adenosine receptor crystallographic structure. Journal of Medicinal Chemistry 2009, 52(10):3284-3292.
52. Jaakola V.P., Griffith M.T., Hanson M.A., Cherezov V., Chien E.Y., Lane J.R., et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008, 322(5905):1211-1217.
53. Jaakola V.P., Ijzerman A.P. The crystallographic structure of the human adenosine A2A receptor in a high-affinity antagonist-bound state: Implications for GPCR drug screening and design. Current Opinion in Structural Biology 2010, 20(4):401-414.
54. Katritch V., Rueda M., Lam P.C., Yeager M., Abagyan R. GPCR 3D homology models for ligand screening: Lessons learned from blind predictions of adenosine A2A receptor complex. Proteins 2010, 78(1):197-211.
55. Kikkawa H., Isogaya M., Nagao T., Kurose H. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. Molecular Pharmacology 1998, 53(1):128-134.
56. Kim S.K., Gao Z.G., Van Rompaey P., Gross A.S., Chen A., Van Calenbergh S., et al. Modeling the adenosine receptors: Comparison of the binding domains of A2A agonists and antagonists. Journal of Medicinal Chemistry 2003, 46(23):4847-4859.
57. Klabunde T., Giegerich C., Evers A. Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening. Journal of Medicinal Chemistry 2009, 52(9):2923-2932.
58. Kobilka B., Schertler G.F. New G-protein-coupled receptor crystal structures: Insights and limitations. Trends in Pharmacological Sciences 2008, 29(2):79-83.
59. Kofuku Y., Yoshiura C., Ueda T., Terasawa H., Hirai T., Tominaga S., et al. Structural basis of the interaction between chemokine stromal cell-derived factor-1/CXCL12 and its G-protein-coupled receptor CXCR4. The Journal of Biological Chemistry 2009, 284(50):35240-35250.
60. Kolb P., Rosenbaum D.M., Irwin J.J., Fung J.J., Kobilka B.K., Shoichet B.K. Structure-based discovery of beta2-adrenergic receptor ligands. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(16):6843-6848.
61. Lagerstrom M.C., Schioth H.B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nature Reviews. Drug Discovery 2008, 7(4):339-357.
62. Li Y.Y., Hou T.J., Goddard W.A. Computational modeling of structure-function of g protein-coupled receptors with applications for drug design. Current Medicinal Chemistry 2010, 17(12):1167-1180.
63. Liaw C.W., Grigoriadis D.E., Lorang M.T., De Souza E.B., Maki R.A. Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Molecular Endocrinology 1997, 11(13):2048-2053.
64. Magnani F., Shibata Y., Serrano-Vega M.J., Tate C.G. Co-evolving stability and conformational homogeneity of the human adenosine A2a receptor. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(31):10744-10749.
65. Martin R.E., Green L.G., Guba W., Kratochwil N., Christ A. Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: A chemogenomics approach. Journal of Medicinal Chemistry 2007, 50(25):6291-6294.
66. McInnes C. Virtual screening strategies in drug discovery. Current Opinion in Chemical Biology 2007, 11(5):494-502.
67. McRobb F.M., Capuano B., Crosby I.T., Chalmers D.K., Yuriev E. Homology modeling and docking evaluation of aminergic G protein-coupled receptors. Journal of Chemical Information and Modeling 2010, 50(4):626-637.
68. Michino M., Abola E., Brooks C.L., Dixon J.S., Moult J., Stevens R.C. Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. Nature Reviews. Drug Discovery 2009, 8(6):455-463.
69. Mittl P.R., Grutter M.G. Opportunities for structure-based design of protease-directed drugs. Current Opinion in Structural Biology 2006, 16(6):769-775.
70. Mobarec J.C., Sanchez R., Filizola M. Modern homology modeling of G-protein coupled receptors: Which structural template to use?. Journal of Medicinal Chemistry 2009, 52(16):5207-5216.
71. Nicholls D.J., Tomkinson N.P., Wiley K.E., Brammall A., Bowers L., Grahames C., et al. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Molecular Pharmacology 2008, 74(5):1193-1202.
72. Nygaard R., Frimurer T.M., Holst B., Rosenkilde M.M., Schwartz T.W. Ligand binding and micro-switches in 7TM receptor structures. Trends in Pharmacological Sciences 2009, 30(5):249-259.
73. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289(5480):739-745.
74. Park J.H., Scheerer P., Hofmann K.P., Choe H.W., Ernst O.P. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 2008, 454(7201):183-187.
75. Parker E.M., Kameyama K., Higashijima T., Ross E.M. Reconstitutively active G protein-coupled receptors purified from baculovirus-infected insect cells. The Journal of Biological Chemistry 1991, 266(1):519-527.
76. Parthier C., Reedtz-Runge S., Rudolph R., Stubbs M.T. Passing the baton in class B GPCRs: Peptide hormone activation via helix induction?. Trends in Biochemical Sciences 2009, 34(6):303-310.
77. Pastorin G., Federico S., Paoletta S., Corradino M., Cateni F., Cacciari B., et al. Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process. Bioorganic & Medicinal Chemistry 2010, 18(7):2524-2536.
78. Patny A., Desai P.V., Avery M.A. Homology modeling of G-protein-coupled receptors and implications in drug design. Current Medicinal Chemistry 2006, 13(14):1667-1691.
79. Pioszak A.A., Parker N.R., Suino-Powell K., Xu H.E. Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1. The Journal of Biological Chemistry 2008, 283(47):32900-32912.
80. Pioszak A.A., Xu H.E. Molecular recognition of parathyroid hormone by its G protein-coupled receptor. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(13):5034-5039.
81. Portoghese P.S. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends in Pharmacological Sciences 1989, 10(6):230-235.
82. Radestock S., Weil T., Renner S. Homology model-based virtual screening for GPCR ligands using docking and target-biased scoring. Journal of Chemical Information and Modeling 2008, 48(5):1104-1117.
83. Rasmussen S.G., Choi H.J., Fung J.J., Pardon E., Casarosa P., Chae P.S., et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 2011, 469(7329):175-180.
84. Rasmussen S.G., Choi H.J., Rosenbaum D.M., Kobilka T.S., Thian F.S., Edwards P.C., et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature 2007, 450(7168):383-387.
85. Reeves P.J., Kim J.M., Khorana H.G. Structure and function in rhodopsin: A tetracycline-inducible system in stable mammalian cell lines for high-level expression of opsin mutants. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(21):13413-13418. [Article].
86. Robertson N., Jazayeri A., Errey J., Baig A., Hurrell E., Zhukov A., et al. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery. Neuropharmacology 2011, 60(1):36-44.
87. Rosenbaum D.M., Zhang C., Lyons J.A., Holl R., Aragao D., Arlow D.H., et al. Structure and function of an irreversible agonist-beta(2) adrenoceptor complex. Nature 2011, 469(7329):236-240.
88. Rubin J.B. Chemokine signaling in cancer: One hump or two?. Seminars in Cancer Biology 2009, 19(2):116-122.
89. Sabio M., Jones K., Topiol S. Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. Bioorganic & Medicinal Chemistry Letters 2008, 18(20):5391-5395.
90. Salchow K., Bond M.E., Evans S.C., Press N.J., Charlton S.J., Hunt P.A., et al. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. British Journal of Pharmacology 2010, 159(7):1429-1439.
91. Sarkar C.A., Dodevski I., Kenig M., Dudli S., Mohr A., Hermans E., et al. Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(39):14808-14813.
92. Scheerer P., Park J.H., Hildebrand P.W., Kim Y.J., Krauss N., Choe H.W., et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 2008, 455(7212):497-502.
93. Schlyer S., Horuk R. I want a new drug: G-protein-coupled receptors in drug development. Drug Discovery Today 2006, 11(11-12):481-493.
94. Schulz M.N., Hubbard R.E. Recent progress in fragment-based lead discovery. Current Opinion in Pharmacology 2009, 9(5):615-621.
95. Sela I., Golan G., Strajbl M., Rivenzon-Segal D., Bar-Haim S., Bloch I., et al. G protein coupled receptors -in silico drug discovery and design. Current Topics in Medicinal Chemistry 2010, 10(6):638-656.
96. Senderowitz H., Marantz Y. G protein-coupled receptors: Target-based in silico screening. Current Pharmaceutical Design 2009, 15(35):4049-4068.
97. Serrano-Vega M.J., Magnani F., Shibata Y., Tate C.G. Conformational thermostabilization of the β1-adrenergic receptor in a detergent-resistant form. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(3):877-882.
98. Shah U., Hodgson R. Recent progress in the discovery of adenosine A2A receptor antagonists for the treatment of Parkinson's disease. Current Opinion in Drug Discovery & Development 2010, 13(4):466-480.
99. Shibata Y., White J.F., Serrano-Vega M.J., Magnani F., Aloia A.L., Grisshammer R., et al. Thermostabilization of the neurotensin receptor NTS1. Journal of Molecular Biology 2009, 390(2):262-277.
100. Smith S.O. Structure and activation of the visual pigment rhodopsin. Annual Review of Biophysics 2010, 39:309-328.
101. Soriano-Ursua M.A., Trujillo-Ferrara J.G., Correa-Basurto J. Scope and difficulty in generating theoretical insights regarding ligand recognition and activation of the beta 2 adrenergic receptor. Journal of Medicinal Chemistry 2010, 53(3):923-932.
102. Soriano-Ursua M.A., Valencia-Hernandez I., Arellano-Mendoza M.G., Correa-Basurto J., Trujillo-Ferrara J.G. Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(t ert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist. European Journal of Medicinal Chemistry 2009, 44(7):2840-2846.
103. Standfuss J., Edwards P.C., D'Antona A., Fransen M., Xie G., Oprion D.D., Schertler G.F. The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 2011, 471:656-660.
104. Talele T.T., Khedkar S.A., Rigby A.C. Successful applications of computer aided drug discovery: Moving drugs from concept to the clinic. Current Topics in Medicinal Chemistry 2010, 10(1):127-141.
105. Tate C.G. Practical considerations of membrane protein instability during purification and crystallisation. Methods in Molecular Biology 2010, 601:187-203.
106. ter Haar E., Koth C.M., Abdul-Manan N., Swenson L., Coll J.T., Lippke J.A., et al. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure 2010, 18(9):1083-1093.
107. Topiol S., Sabio M. Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery. Bioorganic & Medicinal Chemistry Letters 2008, 18(5):1598-1602.
108. Topiol S., Sabio M. X-ray structure breakthroughs in the GPCR transmembrane region. Biochemical Pharmacology 2009, 78(1):11-20.
109. Topiol S., Sabio M., Uberti M. Exploration of structure-based drug design opportunities for mGluRs. Neuropharmacology 2011, 60(1):93-101.
110. Valant C., Gregory K.J., Hall N.E., Scammells P.J., Lew M.J., Sexton P.M., et al. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. The Journal of Biological Chemistry 2008, 283(43):29312-29321.
111. Veldkamp C.T., Seibert C., Peterson F.C., De la Cruz N.B., Haugner J.C., Basnet H. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Science Signaling 2008, 1(37):ra4.
112. Villoutreix B.O., Eudes R., Miteva M.A. Structure-based virtual ligand screening: Recent success stories. Combinatorial Chemistry & High Throughput Screening 2009, 12(10):1000-1016.
113. von Itzstein M., Wu W.Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363(6428):418-423.
114. Wacker D., Fenalti G., Brown M.A., Katritch V., Abagyan R., Cherezov V., et al. Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. Journal of the American Chemical Society 2010, 132(33):11443-11445.
115. Warne T., Moukhametzianov R., Baker J.G., Nehme R., Edwards P.C., Leslie A.G., et al. The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor. Nature 2011, 469(7329):241-244.
116. Warne T., Serrano-Vega M.J., Baker J.G., Moukhametzianov R., Edwards P.C., Henderson R., et al. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 2008, 454(7203):486-491.
117. Weis W.I., Kobilka B.K. Structural insights into G-protein-coupled receptor activation. Current Opinion in Structural Biology 2008, 18(6):734-740.
118. Weiss H.M., Grisshammer R. Purification and characterization of the human adenosine A2a receptor functionally expressed in Escherichia coli. European Journal of Biochemistry 2002, 269(1):82-92.
119. Werge T.M. Identification of an epitope in the substance P receptor important for recognition of the common carboxyl-terminal tachykinin sequence. The Journal of Biological Chemistry 1994, 269(35):22054-22058.
120. Wu B., Chien E.Y., Mol C.D., Fenalti G., Liu W., Katritch V., et al. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists. Science 2010, 332:322-327.
121. Wu B., Chien E.Y., Mol C.D., Fenalti G., Liu W., Katritch V., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330(6007):1066-1071.
122. Yarnitzky T., Levit A., Niv M.Y. Homology modeling of G-protein-coupled receptors with X-ray structures on the rise. Current Opinion in Drug Discovery & Development 2010, 13(3):317-325.